|
| [ На главную ] -- [ Список участников ] -- [ Правила форума ] -- [ Зарегистрироваться ] |
| On-line: |
| Клуб болельщиков "Торпедо" Владимир / / GXKRIicWsKtVQIzGAQB |
| Страницы: 1 |
|
| Автор | Сообщение |
|
Jackson Гость |
Добавлено: 18-08-2021 02:59 |
|
Very interesting tale manforce condoms models AstraZeneca has identified oncology as a core therapy area for building a continued pipeline of innovative medicines and announced earlier this year its plans to begin Phase III trials for olaparib for platinum-sensitive relapsed ovarian cancer patients with BRCA mutations and selumetinib for non small cell lung cancer patients with KRAS mutations. Because of AstraZeneca’s understanding of how cancers grow and how these compounds work, the company is committed to investigating both compounds in a range of solid tumours. |
| Страницы: 1 |
|
| Клуб болельщиков "Торпедо" Владимир / / GXKRIicWsKtVQIzGAQB |